Fortrea Holdings convenes new Site Advisory Board

Fortrea announced it convened last week the inaugural meeting of its Site Advisory Board, a collaboration between clinical research investigator sites and industry leaders to create a better clinical trial experience for sites, patients and clinical study sponsors by targeting changes in technology, operational planning and delivery, commercial terms and community engagement. Fortrea places sites and investigators at the forefront of clinical trial planning, leveraging their perspectives to drive changes that will improve the speed of trial execution, ease study start up and increase recruitment efficiency. These changes address long-standing challenges within clinical trials and will result in a better site, patient and sponsor trial experience. The Site Advisory Board will be responsible for providing insight and feedback on strategies and solutions proposed regarding sites, patients, trial operations and relevant technology. Inaugural members of Fortrea’s Site Advisory Board include leaders and experts from Circuit Clinical, Elligo Health Research, FutureMeds, Javara, MD Anderson Cancer Center Foundation Spain, ObjectiveHealth, Pratia S.A. and Velocity Clinical Research, representing 440 sites across more than 25 therapeutic areas and nine countries and providing access to diverse patient communities.